New study finds continuous glucose monitors improve blood sugar control in people with type 2 diabetes who don't use insulin.

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

Adults with type 2 diabetes who don't use insulin lowered their A1C by 0.9 percentage points more with a continuous glucose monitor (CGM) than with routine care over 26 weeks, according to results ...

Continuous glucose monitoring (CGM) leads to a greater reduction in glycated hemoglobin (HbA1c) levels than routine care for ...

(ISIN US2521311074) plans to release its third-quarter 2026 results on October 29, 2026, making the next earnings report the ...

Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, ...

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

Continuous glucose monitors can dramatically improve blood sugar control among people with type 2 diabetes who aren’t yet ...

South Korea's CGM market reached 57.5 billion won in 2024, with imports holding 92.5% as Daewoong, Huons and i-SENS compete.

A wearable blood sugar monitor may help people with type 2 diabetes even when they don’t need insulin. In a newly published clinical trial, adults using the Dexcom G7 achieved significantly better ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don ...